IDEAS home Printed from
   My bibliography  Save this article

EQ-5D and the EuroQol Group: Past, Present and Future


  • Nancy J. Devlin

    (Office of Health Economics)

  • Richard Brooks

    (EuroQol Group)


Over the period 1987–1991 an inter-disciplinary five-country group developed the EuroQol instrument, a five-dimensional three-level generic measure subsequently termed the ‘EQ-5D’. It was designed to measure and value health status. The salient features of its development and its consolidation and expansion are discussed. Initial expansion came, in particular, in the form of new language versions. Their development raised translation and semantic issues, experience with which helped feed into the design of two further instruments, the EQ-5D-5L and the youth version EQ-5D-Y. The expanded usage across clinical programmes, disease and condition areas, population surveys, patient-reported outcomes, and value sets is outlined. Valuation has been of continued relevance for the Group as this has allowed its instruments to be utilised as part of the economic appraisal of health programmes and their incorporation into health technology assessments. The future of the Group is considered in the context of: (1) its scientific strategy, (2) changes in the external environment affecting the demand for EQ-5D, and (3) a variety of issues it is facing in the context of the design of the instrument, its use in health technology assessment, and potential new uses for EQ-5D outside of clinical trials and technology appraisal.

Suggested Citation

  • Nancy J. Devlin & Richard Brooks, 2017. "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 127-137, April.
  • Handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-017-0310-5
    DOI: 10.1007/s40258-017-0310-5

    Download full text from publisher

    File URL:
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL:
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    1. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
    2. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
    3. MerriKay Oleen-Burkey & Jane Castelli-Haley & Maureen Lage & Kenneth Johnson, 2012. "Burden of a Multiple Sclerosis Relapse," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 5(1), pages 57-69, March.
    4. David G. T. Whitehurst & Stirling Bryan & Martyn Lewis, 2011. "Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores," Medical Decision Making, , vol. 31(6), pages 34-44, November.
    5. R. McQueen & Samuel Ellis & David Maahs & Heather Anderson & Kavita Nair & Anne Libby & Jonathan Campbell, 2014. "Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 7(2), pages 197-205, June.
    6. Petrie, Dennis & Doran, Chris & Shakeshaft, Anthony & Sanson-Fisher, Rob, 2008. "The relationship between alcohol consumption and self-reported health status using the EQ5D: Evidence from rural Australia," Social Science & Medicine, Elsevier, vol. 67(11), pages 1717-1726, December.
    7. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
    8. McNamee, Paul, 2007. "What difference does it make? The calculation of QALY gains from health profiles using patient and general population values," Health Policy, Elsevier, vol. 84(2-3), pages 321-331, December.
    9. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    10. Lyttkens, Carl Hampus & Gerdtham, Ulf-G. & Tinghög, Gustav, 2018. "Do We Know What We Are Doing? An Exploratory Study on Swedish Health Economists and the EQ-5D," Working Papers 2018:40, Lund University, Department of Economics.
    11. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    12. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    13. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    14. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
    15. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    16. Victoria Brennan & Simon Dixon, 2013. "Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies," PharmacoEconomics, Springer, vol. 31(8), pages 677-691, August.
    17. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    18. Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass, 2006. "Costs and quality of life of multiple sclerosis in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 14-23, July.
    19. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
    20. Richard Holland & Richard D Smith & Ian Harvey & Louise Swift & Elizabeth Lenaghan, 2004. "Assessing quality of life in the elderly: a direct comparison of the EQ‐5D and AQoL," Health Economics, John Wiley & Sons, Ltd., vol. 13(8), pages 793-805, August.


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-017-0310-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.